1099-1263/asset/JAT_left.gif?v=1&s=3861b4e1a7a7422dd2d5714a3e46e7e26b56e36e)
1099-1263/asset/JAT_right.gif?v=1&s=84d6e73c4b9ec6a5179cb5dba03191c024ed3482)
Review
Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia
Article first published online: 2 SEP 2011
DOI: 10.1002/jat.1723
Copyright © 2011 John Wiley & Sons, Ltd.
Additional Information
How to Cite
Hargreaves, A. and Harleman, J. (2011), Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia. J. Appl. Toxicol., 31: 599–607. doi: 10.1002/jat.1723
Publication History
- Issue published online: 24 OCT 2011
- Article first published online: 2 SEP 2011
- Manuscript Revised: 8 JUL 2011
- Manuscript Accepted: 8 JUL 2011
- Manuscript Received: 23 MAY 2011
- Abstract
- Article
- References
- Cited By
Keywords:
- drug-induced;
- prolactin;
- hypoprolactinemia;
- hyperprolactinemia;
- risk assessment
ABSTRACT
Drug-induced changes in prolactin signaling may obscure interpretation of preclinical toxicological endpoints. However, with informed consideration, classic hallmarks of hypo-/hyperprolactinemia can be recognized in short- and long-term rodent bioassays. Findings can be supported and expanded with additional in vivo and in vitro datasets. When taken together with human epidemiological evidence pertaining to the consequences of drug-induced hypo-/hyperprolactinemia, such findings permit both an analysis of human relevance and an assessment of human risk. Copyright © 2011 John Wiley & Sons, Ltd.